November 19, 2025

Diabetes Hearing Loss Link Confirmed

Meta-analysis reveals disease duration and blood sugar control as key factors in auditory decline

Conexiant

November 18, 2025

Plozasiran Wins FDA Nod for FCS

Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.

Conexiant

November 18, 2025

‘Designed to Scare People’? New Contraception Data

Hormonal contraception shows overall safety with a modest, short-term rise in breast cancer risk.

KFF Health News

November 14, 2025

The Risk Factor Going Unscreened

Adverse childhood experiences drive elevated all-cause mortality across medical conditions, with emergency department patients also showing nearly double the death rates.

Conexiant

November 12, 2025

Dual Therapy for Coronary Disease: How Safe Is It? 

Adding aspirin to long-term oral anticoagulation in patients with chronic coronary syndrome increased mortality and major bleeding without improving cardiovascular outcomes.

Conexiant

November 11, 2025

Gene Editing Lowers Cholesterol in Early Trial

At the highest tested dose, a single IV CRISPR therapy reduced LDL cholesterol by ~49% and triglycerides by ~55% at 60 days in patients with treatment-resistant dyslipidemia.

Conexiant

November 10, 2025

FDA Proposes Removal of Box Warnings

The FDA proposed updates to menopausal hormone therapy labeling to reflect current evidence on benefits and risks.

Conexiant

November 06, 2025

Exercise Patterns and GI Cancer Risk

Consistently meeting—but not exceeding—recommended activity levels offers maximal protection against digestive cancers, new research suggests.

Conexiant

November 04, 2025

Should SGLT-2 Inhibitors Be Continued After a UTI?

Patients with type 2 diabetes who developed urinary tract infections while taking sodium-glucose cotransporter-2 inhibitors faced higher heart and kidney risks.

Conexiant